Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)

(2021) Florian Kocher et al.   Translational Lung Cancer Research

Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade

(2021) Wei Si et al.   GUT

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

(2021) Diwakar Davar et al.   SCIENCE

Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

(2021) Maria Tsikala-Vafea et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

(2020) Andrea Botticelli et al.   Journal of Translational Medicine

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

Gut microbiota-derived metabolites as key actors in inflammatory bowel disease

(2020) Aonghus Lavelle et al.   Nature Reviews Gastroenterology & Hepatology

Microbiome analyses of blood and tissues suggest cancer diagnostic approach

(2020) Gregory D. Poore et al.   NATURE

Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast

(2020) Tsengelmaa Jamiyan et al.   Breast Cancer

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

(2020) Clélia Coutzac et al.   Nature Communications

Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer

(2020) M. Karayama et al.   Clinical & Translational Oncology

Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication

(2020) Giuseppe Lamberti et al.   Future Oncology

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

(2020) Lukas F. Mager et al.   SCIENCE

Commensal bacteria stimulate antitumor responses via T cell cross-reactivity

(2020) Catherine A. Bessell et al.   JCI Insight

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors

(2020) Motoo Nomura et al.   JAMA Network Open

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

(2020) Erez N. Baruch et al.   SCIENCE

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

(2020) Denis L. Jardim et al.   CANCER CELL

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

(2019) Arielle Elkrief et al.   OncoImmunology

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

(2019) Takeshi Tanoue et al.   NATURE

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Benefits and limitations of genome-wide association studies

(2019) Vivian Tam et al.   NATURE REVIEWS GENETICS

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

(2019) Hamzah Abu-Sbeih et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2019) David J. Pinato et al.   JAMA Oncology

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

(2019) Douglas Donnelly et al.   Journal for ImmunoTherapy of Cancer

Harnessing innate immunity in cancer therapy

(2019) Olivier Demaria et al.   NATURE

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

(2019) Haoxin Li et al.   Nature Communications

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

(2018) L Derosa et al.   ANNALS OF ONCOLOGY

The intestinal microbiome influences checkpoint blockade

(2018) Cynthia L Sears et al.   NATURE MEDICINE

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology

(2018) Shuji Ogino et al.   Annual Review of Pathology-Mechanisms of Disease

Microbial tryptophan catabolites in health and disease

(2018) Henrik M. Roager et al.   Nature Communications

Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors

(2018) Jibran Ahmed et al.   OncoImmunology

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens

(2017) Sohn Kim et al.   IMMUNOLOGICAL REVIEWS

Towards standards for human fecal sample processing in metagenomic studies

(2017) Paul I Costea et al.   NATURE BIOTECHNOLOGY

Bifidobacteriumcan mitigate intestinal immunopathology in the context of CTLA-4 blockade

(2017) Feng Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

(2016) Romain Daillère et al.   IMMUNITY

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

(2016) Jonathan M. Pitt et al.   OncoImmunology

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

Intestinal Commensal Microbes as Immune Modulators

(2012) Ivaylo I. Ivanov et al.   Cell Host & Microbe

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interactions Between the Microbiota and the Immune System

(2012) L. V. Hooper et al.   SCIENCE

Fecal microbiota transplantation and emerging applications

(2011) Thomas J. Borody et al.   Nature Reviews Gastroenterology & Hepatology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases

(2009) Steven C. Katz et al.   ANNALS OF SURGICAL ONCOLOGY